| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Signaling in Mouse Macrophages: Toll-Like Receptor 2 Stimulation Increases Expression of Dominant-Negative STAT1
by mRNA Stabilization 1
Departments of
*
Molecular Virology, Immunology, and Medical Genetics, and
Microbiology, Ohio State University, Columbus, OH 43210
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
. We previously reported that Mycobacterium avium infection of mouse macrophages decreases IFN--induced STAT1 tyrosine phosphorylation and STAT1 DNA binding. Because macrophages respond to M. avium through Toll-like receptor 2 (TLR2), we determined whether TLR2 stimulation inhibits the response to IFN-. Treatment of mouse RAW264.7 macrophages with TLR2 agonists inhibited the induction of IFN--inducible genes by IFN-. In contrast to M. avium infection, TLR2 agonists did not inhibit the IFN- induction of DNA-binding activity of STAT1 and the tyrosine phosphorylation of STAT1
. Instead, IFN- induction of RAW264.7 cells treated with TLR2 agonists resulted in an increase in the tyrosine phosphorylation of the dominant-negative STAT1
. TLR2 stimulation of RAW264.7 cells increased both STAT1 protein and mRNA expression, suggesting that the increased STAT1 phosphorylation results from increased STAT1 expression. Because STAT1 and STAT1 mRNA have different 3' untranslated regions, and 3' untranslated regions can regulate mRNA stability, we examined the effects of TLR2 stimulation on mRNA stability. TLR2 stimulation of RAW264.7 cells increased the stability of STAT1 mRNA, while not affecting the stability of STAT1 mRNA. The ability of STAT1 to function as a dominant negative was confirmed by overexpression of STAT1 in RAW264.7 macrophages by transient transfection, which inhibited IFN--induced gene expression. These findings suggest that M. avium infection of mouse macrophages inhibits IFN- signaling through a TLR2-dependent increase in STAT1 expression by mRNA stablization and a TLR2-independent inhibition of STAT1 tyrosine phosphorylation. |
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
, a cytokine produced by activated T and NK cells, plays a key role in host defense mechanisms. Mice with a disrupted IFN- gene are more susceptible to intracellular pathogens such as Leishmania major (1), Listeria monocytogenes (2), and Mycobacterium tuberculosis (3, 4). IFN- exerts its effects on immunity to intracellular pathogens by activating antimicrobial resistance mechanisms of macrophages (5). IFN- induces gene expression by the Janus kinase (JAK)
3/STAT signaling pathway (6, 7, 8). Binding of IFN- to its receptor results in phosphorylation of STAT1 by Janus kinases, JAK1 and JAK2. The phosphorylated STAT1 is then translocated to the nucleus to activate gene transcription. STAT1 exists in two forms as the result of alternative RNA splicing, STAT1 (p91) and STAT1 (p84) (9). STAT1 has 38 aa at the C terminus that are absent in STAT1. Only STAT1 is able to activate transcription of IFN--inducible genes (10, 11), as the C-terminal region of STAT1 is required for interaction with transcriptional coactivator CREB-binding protein (CBP)/p300 (12). Thus, STAT1 is thought to act as a dominant-negative inhibitor of IFN-.
Mononuclear phagocytes infected with mycobacteria have reduced ability to respond to IFN-, resulting in low expression of MHC II genes and other IFN--induced genes (13, 14, 15, 16, 17, 18). Studies from this laboratory (17) have investigated the mechanism involved in the inhibition of IFN- signaling by infection with Mycobacterium avium. Infected mouse macrophages stimulated with IFN- were found to have decreased STAT1 DNA binding and tyrosine phosphorylation. Decreased STAT1 activation was correlated with decreased tyrosine phosphorylation of JAK1, JAK2, and IFN- receptor -chain. We also observed a decrease in the expression of the IFN- receptor in M. avium-infected macrophages. However, infection of human monocytes with M. tuberculosis was shown by Ting et al. (18) to inhibit IFN--induced FcR1 gene expression, but had no effect on the activation of STAT1 by the JAK/STAT signaling pathway. They observed a reduction in the interaction of STAT1 with the transcriptional coactivator CBP/p300, suggesting that M. tuberculosis is affecting the ability of activated STAT1 to induce gene transcription. These studies suggest that mycobacterial infection can interfere with IFN- signaling at multiple steps in the JAK/STAT pathway.
The interaction of mycobacterial products with Toll-like receptors (TLR) expressed by the macrophage initiates the proinflammatory response of macrophages and induces antimicrobial activity (19, 20, 21, 22, 23). M. avium stimulates macrophages through TLR2, while M. tuberculosis stimulates through both TLR2 and TLR4 (23, 24, 25). The mycobacterial products that interact with TLR2 include lipoarabinomannan, phosphatidylinositolmannan, and a 19-kDa lipoprotein from M. tuberculosis (23, 26, 27, 28). In the current study, we examined the effect of stimulation of TLR2 on the IFN- activation of mouse RAW264.7 macrophages. We found that prior TLR2 stimulation reduces gene expression induced by IFN-. TLR2 stimulation did not alter IFN--induced STAT1 DNA binding and phosphorylation of STAT1. Our studies suggest that TLR2 stimulation instead inhibits IFN--induced gene expression by increasing the expression of the transcriptionally inactive STAT1 through mRNA stabilization. Upon IFN- activation, higher levels of STAT1 are tyrosine phosphorylated in the TLR2-stimulated macrophages, reducing the transcriptional response of the macrophage to IFN-. Furthermore, the ability of STAT1 to act as a dominant negative was confirmed by overexpressing STAT1 by transient transfection of RAW264.7 cells, which reduced gene expression induced by IFN-.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
FBS was purchased from Harlan Bioproducts for Science (Indianapolis, IN). Mouse IFN- and DNA polymerase (Klenow fragment) were obtained from Invitrogen (Carlsbad, CA). Actinomycin D was obtained from Sigma-Aldrich (St. Louis, MO). [32P]dCTP (3000 Ci/mmol) was obtained from Amersham (Piscataway, NJ). Pam3CSK4 was acquired from EMC Microcollections (Tübingen, Germany). Lipoarabinomannan purified from Mycobacterium smegmatisand 19-kDa lipoprotein purified from M. tuberculosis were obtained from the National Institutes of Health Tuberculosis Research Materials Contract AI-75320, Colorado State University (Fort Collins, CO).
Mycobacteria
M. avium (ATCC 35713) was initially passed once in mice and then cultured in Middlebrook 7H9 broth (Difco, Detroit, MI) to mid-log phage, aliquoted in 1-ml amounts at 2 x 108 CFU/ml, and stored frozen in 10% glycerol at -80°C.
Mice
C57BL/6 mice were purchased from Harlan Sprague Dawley (Indianapolis, IN) at 4–6 wk. The mice were used as macrophage donors when 6–10 wk of age.
Cell culture
Murine RAW264.7 macrophages, obtained from the American Type Culture Collection (Manassas, VA), were cultured in DMEM supplemented with 10% FBS, 5 mM sodium pyruvate, 100 U/ml penicillin, and 100 µg/ml streptomycin. Mouse peritoneal macrophages were obtained by lavage of mice that had been injected with 4% thioglycolate broth (Difco) 4 days previously. RAW264.7 cells and peritoneal macrophages were seeded in six-well plates at 5 x 106 cells/well. RAW264.7 cells were cultured for 4 h before addition of M. avium and TLR2 agonists. Peritoneal macrophages were cultured overnight, nonadherent cells were removed by washing with HBSS, and adherent cells were treated with M. avium and TLR2 agonists. The expression of IFN--inducible genes MHC class II Eb and IFN regulatory factor 1 (IRF1) was determined by Northern blot hybridization. RAW264.7 macrophages were cultured for 16 h with TLR2 agonists (lipoarabinomannan, 19-kDa M. tuberculosis lipoprotein, Pam3CSK4) and M. avium (10:1) and stimulated with IFN- (200 U/ml) for 20 h. RNA was isolated by the method of Chomczynski and Sacchi (29). The effect of TLR2 agonists on STAT1 mRNA expression was examined by treating RAW264.7 macrophages with TLR2 agonists and isolating RNA at the indicated times. For EMSA and Western blotting, cells treated with TLR2 agonists for 16 h were stimulated with IFN- (200 U/ml) for 45 min.
Northern blot hybridization
RNA (15 µg) was separated in 1% formaldehyde agarose gels and transferred to Hybond-N+ membranes by capillary blotting. Northern blot hybridization was performed, as previously described (30). The cDNA probe to IRF1 was obtained by RT-PCR of IFN--stimulated RAW264.7 macrophages using primers 5'-CCAAGAGGAAGCTGTGTGGAG-3' (sense) and 5'-CAGCAGGCTGTCCATCCACATG-3' (antisense) (31). cDNA clones of MHC class II Eb, STAT1, T cell GTP-binding protein (TGTP), and G3PDH were isolated from a cDNA library of IFN--stimulated macrophages, and identity was confirmed by DNA sequencing. The probes were labeled with [32P]dCTP by the High Prime labeling system.
Measurement of STAT1 mRNA stability
To measure the effects of TLR2 agonists on STAT1 mRNA stability, RAW264.7 cells were cultured in six-well tissue plates with/without 2 µg/ml Pam3CSK4. After 16 h, transcription was inhibited by the addition of actinomycin D (2 µg/ml). RNA was then isolated at 0, 1, 2, 4, 6, and 8 h. STAT1 and STAT1 mRNA were detected by Northern blot hybridization, as described. Autoradiographs were scanned with a Epson scanner and quantified using SigmaScan Pro 4 (SPSS, Chicago, IL). To account for differences in loading, blots were hybridized with the G3PDH cDNA probe, and STAT1 mRNA signals were normalized with the G3PDH signal. Linear regression analysis of semilogarithmic plots of percentage of STAT1 mRNA remaining vs time after addition of actinomycin D was used to determine mRNA t1/2.
EMSA
Nuclear extracts were prepared from 107 RAW264.7 cells, as described previously (32). EMSAs were done in 20 µl binding reactions containing 7.5 µg of nuclear protein, 10 mM Tris-HCl, pH 7.5, 50 mM NaCl, 5 mM DTT, 5 mM MgCl2, 10% glycerol, 0.20% Nonidet P-40, 1 µg of poly(dI-dC), and 100,000 cpm of 32P-labeled IFN- activation site (GAS) probe. The GAS probe used (5'-AGCCATTTCCAGGAATCGAAA-3') contains the optimum GAS sequence (TTCCSGGAA) for STAT1 DNA binding (32). The double-stranded GAS oligonucleotide probe was radiolabeled with [32P]dCTP by fill-in reaction with Klenow DNA polymerase. Binding reactions were incubated for 20 min at room temperature and then separated on 5% polyacrylamide gels in 0.50x Tris-borate-EDTA. Gels were dried and analyzed by autoradiography.
Western blot analysis
RAW264.7 cells and peritoneal macrophages were incubated with TLR2 agonists and IFN-, as described above. Following treatment with IFN-, cells were solubilized in lysis buffer containing 20 mM Tris-HCl, pH 8, 1% Trition X-100, 137 mM NaCl, 10% glycerol, and 20 µl/ml Protease Arrest (Calbiochem, San Diego, CA). Cell debris was removed by centrifugation at 4°C at 14,000 x g for 15 min. Protein concentrations were determined by the Bradford method using Bio-Rad protein assay reagent (Bio-Rad, Richmond, CA). Samples (25 µg) were separated by SDS-PAGE using 10% Tris-glycine gels (Invitrogen), followed by transfer to Immobilon P membranes (Millipore, Bedford, MA). Membranes were blocked in 5% Quickblocker (GenoTech, St. Louis, MO) in TBS containing 0.05% Tween 20 for 1 h and incubated with primary Abs overnight. The detection step was performed with peroxidase-coupled anti-mouse IgG and anti-rabbit IgG Abs (GenoTech; 1:7500). Primary Abs were monoclonal anti-phosphoSTAT1 (Zymed, South San Francisco, CA; 1:2000) and STAT1 p84/p91 rabbit Ab (Santa Cruz Biotechnology, Santa Cruz, CA; 1:3000). Blots were developed with the femtoLucent detection system (GenoTech).
Transient transfection
A STAT1 expression vector was constructed by PCR amplification of the coding region of a STAT1 plasmid obtained from the American Type Culture Collection (I.M.A.G.E. clone 358731) and cloning of the PCR product into the pcDNA 3.1+ expression vector (Invitrogen) using BamHI and XbaI sites. Sequence of the pcDNA-STAT1 plasmid was confirmed by DNA sequencing. RAW264.7 cells (2 x 106 cells/well) in six-well plates were transfected with varying amounts of the pcDNA-STAT1 plasmid or pCDNA3.1 vector by lipofection using Lipofectamine Plus (Invitrogen), according to manufacturer’s instructions. After overnight incubation, duplicate wells were stimulated with 200 U/ml IFN-. After 45 min, cellular lysates were prepared from one set of wells, and phospho-STAT1 was determined by Western blotting, as described above. RNA was isolated from the second set of wells after 8 h, and gene induction by IFN- was determined by Northern blotting.
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
-induced gene expression
To examine the effects of TLR2 activation on gene induction by IFN-, RAW264.7 macrophages were stimulated for 16 h with TLR2 agonists, lipoarabinomannan (26), 19-kDa lipoprotein from M. tuberculosis (28), and a synthetic lipoprotein Pam3CSK4 (19). The macrophages were then activated for 20 h with IFN-. IFN--induced gene expression was assessed by Northern blot hybridization (Fig. 1). Each of the TLR2 agonists completely inhibited IFN- induction of MHC class II Eb mRNA, while dramatically inhibiting induction of IRF1 and TGTP, a putative GTP-binding protein (30, 33). The level of inhibition is identical with that observed in M. avium-infected macrophages. Eb expression in macrophages is regulated by IFN- induction of class II transactivator by STAT1 and IRF1 activation (5). Both IRF1 and TGTP expression are regulated directly by STAT1 activation (5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30).
|
The effects of TLR2 stimulation on IFN--induced STAT1 activation were assessed by EMSA using a double-stranded oligonucleotide containing the consensus GAS sequence for STAT1 DNA binding (34). RAW264.7 macrophages were stimulated with lipoarabinomannan and Pam3CSK4 for 16 h and then activated with IFN- for 45 min. As shown in Fig. 2A, neither of the TLR2 agonists inhibited the STAT1 DNA-binding activity. In contrast, infection with M. avium inhibited STAT1 binding, as previously reported (17). Specificity for STAT1 was confirmed by Ab supershift using a STAT1 p84/p91 Ab (Fig. 2B).
|
We used Western blot analysis to study the tyrosine phosphorylation of STAT1 and STAT1 induced by IFN- in RAW264.7 macrophages stimulated for 16 h with TLR2 agonists. As shown in Fig. 3A, IFN- activation of unstimulated RAW264.7 macrophages resulted in phosphorylation of predominantly STAT1. The ratio of phosphorylated STAT to phosphorylated STAT1 was 5:1 (Fig. 3C). In RAW264.7 macrophages stimulated with the TLR2 agonists, IFN- induced the same level of STAT1 phosphorylation as unstimulated RAW264.7 macrophages (Fig. 3, A and B). In contrast, there was a 5-fold increase in STAT1 phosphorylation in TLR2 agonist-stimulated RAW264.7 cells. This reduced the ratio of phosphorylated STAT1/STAT1 to 
1:1 (Fig. 3C). A similar increase in STAT1 phosphorylation was also observed in mouse peritoneal macrophages stimulated with Pam3CSK4 and lipoarabinomannan (data not shown). In RAW264.7 cells infected with M. avium at 10:1, the ratio of phosphorylated STAT1/STAT1 induced by IFN- was also reduced compared with RAW264.7 treated with IFN- alone. At the higher ratio of 20:1 bacteria/macrophage ratio, inhibition of tyrosine phosphorylation of both STAT1 and STAT1 was observed (Fig. 3, A and B), as previously reported. These data provide evidence that TLR2 stimulation shifts the phosphorylation of STAT1 from a predominantly STAT1 phosphorylation in unstimulated cells to equal phosphorylation of the transcriptionally active STAT1 and transcriptionally inactive STAT1. To further study the effect of TLR2 stimulation on STAT1 phosphorylation, RAW264.7 macrophages were stimulated with increasing concentrations of lipoarabinomannan (Fig. 4). Lipoarabinomannan stimulation had no effect on phosphorylation of STAT1 induced by IFN-, but dose dependently increased phosphorylation of STAT1 (Fig. 4, A and B). The blot was then stripped and reprobed with a p91/p84 STAT1 Ab to detect total STAT1 protein levels. Lipoarabinomannan stimulation increased the protein level of STAT1 by 2-fold, while only slightly increasing STAT protein levels (Fig. 4, A and C).
|
|
mRNA levels by stabilizing STAT1 mRNA
Because the Western blot analysis showed that protein levels of STAT1 are increased by TLR2 stimulation, we examined the mRNA levels of STAT1 and STAT1 in RAW264.7 macrophages stimulated for 16 h with Pam3CSK4. RNA was isolated, and Northern blots were hybridized with a STAT1 cDNA probe that detects both STAT1 and STAT1 mRNA. As shown in Fig. 5, Pam3CSK4 increased STAT1 mRNA levels to a greater extent than STAT1 mRNA. Identical results were obtained using lipoarabinomannan (data not shown).
|
and STAT1 are transcribed from the same gene and result from alternate splicing of the transcript (9). Thus, differences in levels of STAT1 and STAT1 mRNA must be posttranscriptionally regulated. As a result of the alternate splicing, STAT1 and STAT1 mRNA differ in the 3' untranslated region. Because mRNA stability can be regulated by sequences in the 3' untranslated region of mRNA (35), we examined whether TLR2 stimulation influences the stability of STAT1 and STAT1 mRNA. RAW264.7 macrophages were activated by incubation with Pam3CSK4 for 16 h. Actinomycin D was then added to the TLR2-stimulated and control-unstimulated RAW264.7 macrophages. At various times following addition of actinomycin D, RNA was isolated and STAT1 mRNA decay was analyzed by Northern blot hybridization. In control-unstimulated RAW264.7 cells, STAT1 mRNA was more stable than STAT1 mRNA (Fig. 6). TLR2 stimulation did not change the stability of STAT1 mRNA. However, TLR2 stimulation greatly increased stability of STAT1 mRNA. As the result, STAT1 mRNA was more stable in TLR2-stimulated cells than STAT1.
|
inhibits IFN--induced gene expression
The above studies suggest that transcriptionally inactive STAT1 may be acting as dominant-negative inhibitor of IFN- in TLR2-stimulated macrophages. However, although transfection studies have shown that STAT1 is transcriptionally inactive, studies have not been done to determine whether STAT1 acts as dominant negative when both STAT1 and STAT1 are expressed. To test whether STAT1 can act as a dominant negative in RAW264.7 cells, RAW264.7 cells were transiently transfected with increasing concentrations of a STAT1 pcDNA expression vector. The transfected cells were stimulated with IFN-, and the effect on STAT1 phosphorylation and IFN--induced gene expression was examined (Fig. 7). As shown in Fig. 7, A and B, transfection with the STAT1 expression vector increased STAT1 phosphorylation, resulting in reduced phosphorylated STAT1/STAT1 ratios with increasing amounts of the STAT1 expression vector. Transfection with the empty pcDNA3.1 vector had only a minimal effect on STAT1 phosphorylation. Transfection with STAT1 expression inhibited IFN--induced IRF1, TGTP, and MHC class II Eb gene expression in a dose-dependent manner (Fig. 7C). At 2 µg of STAT1 expression vector, inhibition was 33% for IRF1, 46% for TGTP, and 47% for Eb (Fig. 7D).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
. In the current study, we report that prior stimulation with TLR2 agonists also inhibits IFN- gene induction of several IFN--inducible genes, including the MHC class II Eb gene. Similar inhibition of IFN--induced MHC class II expression by TLR2 agonists 19-kDa lipoprotein and lipoarbinomannan have also been previously reported (36, 37, 38). We began these studies to determine whether TLR2 stimulation might account for our previous observation that M. avium infection of mouse macrophages inhibits IFN- activation of the JAK/STAT signaling pathway (17). Studies have shown that TLR2 stimulation accounts for the M. avium induction of proinflammatory cytokines in mouse macrophages (19, 20, 21). However, in contrast to M. avium infection, which inhibited STAT1 tyrosine phosphorylation and DNA binding, TLR2 stimulation did not inhibit STAT1 DNA binding or STAT1 tyrosine phosphorylation. Instead, we found that TLR2 stimulation increased the level of tyrosine-phosphorylated STAT1. In control RAW264.7 cells stimulated with IFN-, the ratio of phosphorylated STAT1/STAT1 was 5:1. In TLR2 agonist-treated RAW264.7 cells stimulated with IFN-, the ratio decreased to near 1:1. STAT1 lacks 38 aa at the C terminus that are required for transcriptional activation. The C terminus is required for interaction of STAT1 with transcriptional coactivator CBP/p300 (12). Overexpression of STAT1 by transient transfection of STAT1-deficient cells results in cells that are not responsive to IFN- (10, 11), indicating that STAT1 may act as a dominant negative. This was confirmed in our studies by transient tranfection of RAW264.7 cells with STAT1, which resulted in partial inhibition of IFN--induced IRF1, TGTP, and class II Eb expression. Thus, the increase in STAT1 tyrosine phosphorylation in TLR2-stimulated RAW264.7 cells is a mechanism by which IFN--induced gene expression is inhibited. However, while overexpression of STAT1 results in partial inhibition of IFN--induced MHC class II Eb expression, stimulation by TLR2 agonists results in almost complete inhibition of IFN--induced Eb gene expression. This suggests another mechanism may also be involved in TLR2 inhibition of MHC class II expression. More in-depth studies of the effects of TLR2 agonists on MHC class II expression are in progress.
M. avium infection at 10:1 also increased STAT1 phosphorylation and lowered the ratio of phosphorylated STAT1/STAT1. This suggests that this TLR2 pathway is activated by M. avium infection. Inhibition of tyrosine phosphorylation of STAT1 and STAT1 and inhibition of STAT1 DNA-binding activity were observed in RAW264.7 macrophages infected with M. avium at 20:1, which is consistent with our previous studies. This inhibition of phosphorylation appears to be independent of TLR2 stimulation and requires a high level of infection. The mechanism responsible for this second pathway of inhibiting IFN--induced gene expression remains unknown, but is also currently under investigation.
Our results in this study with TLR2 agonists are very similar to studies of Ting et al. (18), who showed that infection of human monocytes with M. tuberculosis inhibited IFN--induced gene expression. Similarly, JAK/STAT signaling was not inhibited. They observed, using in vitro pull-down experiment with a GAS oligonucleotide, that STAT1 from infected cells bound less of the transcriptional coactivator CBP/p300 than STAT1 from control cells. They concluded that M. tuberculosis infection is inhibiting the interaction of STAT1 with the transcriptional coactivator. Because STAT1 is unable to interact with CBP/p300 (12), their observation can be explained by an increase in phosphorylation of STAT1. Examination of their Western blots shows an increase in STAT1 expression and tyrosine phosphorylation that is comparable to the increase induced in mouse macrophages with TLR2 agonists. Thus, we suggest that TLR2 stimulation of human monocytes by M. tuberculosis is also increasing STAT1 expression and that this accounts for the inhibition of IFN--induced gene transcription by M. tuberculosis in human monocytes.
We also found in this study that TLR2 stimulation preferentially increases STAT1 mRNA and protein expression. Thus, it is likely that the increased levels of tyrosine-phosphorylated STAT1, in TLR2 agonist-treated cells, are due to the increase in STAT1 expression. However, STAT1 and STAT1 result from alternative splicing of the same gene transcript (9), thus eliminating transcriptional regulation as a possible mechanism for the differential expression of STAT1 and STAT1 mRNA. We therefore explored whether the differential expression is the result of posttranscriptional regulation. There are two possible pathways by which STAT1 and STAT1 mRNA could be posttranscriptionally regulated. TLR2 stimulation could be affecting the level of expression or activity of the splicing factor involved in generating the STAT1 mRNA transcript. However, the splicing factor has not been identified. As a consequence of the alternative splicing, STAT1 and STAT1 mRNA have different 3' untranslated regions. Because mRNA stability is often regulated through the 3' untranslated region (35), the differential expression could result from differences in mRNA stability. In fact, our results show that TLR2 stimulation dramatically increases stability of the STAT1 mRNA, while not affecting the stability of STAT1 mRNA. We suggest that TLR2 stimulation regulates STAT1 mRNA stability by regulating the expression or activity of proteins that bind to the STAT1 mRNA and stabilize the mRNA. Our results do not preclude the possibility that TLR2 stimulation is regulating activity of the splicing factor, because splicing factor ASF/SF2 has been shown to also regulate mRNA stability (39).
In conclusion, infection of macrophages with mycobacteria inhibits the ability of the macrophage to respond to IFN-. Several diverse pathways are involved in the inhibition of IFN- signaling by M. avium infection of mouse macrophages. One of these pathways is the increase in the expression of the dominant-negative STAT1 by TLR2 stimulation. This occurs through preferential stabilization of STAT1 mRNA. These studies indicate that STAT1 is not just a curiosity of the JAK/STAT pathway, but is a pathway through which IFN--induced gene expression can be down-regulated by pathogen interaction with TLR2. Such a down-regulation of IFN- signaling would be to the advantage of a pathogen because it would depress the IFN- induction of antimicrobial pathways.
|
Footnotes |
|---|
2 Address correspondence and reprint requests to Dr. William P. Lafuse, Department of Molecular Virology, Immunology, and Medical Genetics, Ohio State University, 333 West 10th Avenue, Columbus, OH 43210. E-mail address: lafuse.1{at}osu.edu
3 Abbreviations used in this paper: JAK, Janus kinase; GAS, IFN- activation site; IRF1, IFN regulatory factor 1; TGTP, T cell GTP-binding protein; TLR, Toll-like receptor; CBP, CREB-binding protein.
Received for publication January 30, 2003. Accepted for publication October 7, 2003.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
-deficient mice infected with Leishmania major. J. Exp. Med. 179:1367.. Immunity 3:109.[Medline]
disrupted mice. J. Exp. Med. 178:2243. in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178:2249.. Annu. Rev. Immunol. 15:749.[Medline]
. Proc. Natl. Acad. Sci. USA 89:7836. and - signal transduction pathways. EMBO J. 12:4221.[Medline]
and interferon . Proc. Natl. Acad. Sci. USA 93:7673. signaling. Proc. Natl. Acad. Sci. USA 93:15092. Janus kinase-STAT signaling and gene induction by down-regulation of the IFN- receptor. J. Immunol. 163:2041. transcriptional responses without inhibiting activation of STAT1. J. Immunol. 163:3898.-induced in mouse peritoneal macrophages and encodes a putative GTP-binding protein. J. Leukocyte Biol. 57:477.[Abstract]
responsive elements in two maturationally distinct macrophage cell lines. J. Immunol. 155:4933.[Abstract]
sequences motifs controls interferon- and lipopolysacharide-stimulated transcription from the mouse IP-10 promoter. J. Biol. Chem. 268:6667.
interferon-mediated activation of macrophages. Infect. Immun. 56:1232.
-induced class II transactivator expression by 19-kDa lipoprotein from Mycobacterium tuberculosis: a potential mechanism for immune evasion. J. Immunol. 171:175.This article has been cited by other articles:
|
|
 |
|
  I. Najjar, P. O. Schischmanoff, F. Baran-Marszak, P.-A. Deglesne, I. Youlyouz-Marfak, M. Pampin, J. Feuillard, G. W. Bornkamm, M. K. Chelbi-Alix, and R. Fagard Novel function of STAT1{beta} in B cells: induction of cell death by a mechanism different from that of STAT1{alpha} J. Leukoc. Biol., December 1, 2008; 84(6): 1604 - 1612. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Verma and S. Swaminathan Epstein-Barr Virus SM Protein Functions as an Alternative Splicing Factor J. Virol., July 15, 2008; 82(14): 7180 - 7188. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. J. Ryu, E. J. Kim, S-H. Lee, S. Y. Kim, G. Y. Suh, M. P. Chung, H. Kim, O. J. Kwon, and W-J. Koh Impaired expression of Toll-like receptor 2 in nontuberculous mycobacterial lung disease Eur. Respir. J., October 1, 2007; 30(4): 736 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Puppo, M. C. Bosco, M. Federico, S. Pastorino, and L. Varesio Hypoxia inhibits Moloney murine leukemia virus expression in activated macrophages J. Leukoc. Biol., February 1, 2007; 81(2): 528 - 538. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Pennini, R. K. Pai, D. C. Schultz, W. H. Boom, and C. V. Harding Mycobacterium tuberculosis 19-kDa Lipoprotein Inhibits IFN-{gamma}-Induced Chromatin Remodeling of MHC2TA by TLR2 and MAPK Signaling J. Immunol., April 1, 2006; 176(7): 4323 - 4330. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. G. Netea, J. W. M. Van der Meer, R. P. Sutmuller, G. J. Adema, and B.-J. Kullberg From the Th1/Th2 Paradigm towards a Toll-Like Receptor/T-Helper Bias Antimicrob. Agents Chemother., October 1, 2005; 49(10): 3991 - 3996. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Forget, D. J. Gregory, and M. Olivier Proteasome-mediated Degradation of STAT1{alpha} following Infection of Macrophages with Leishmania donovani J. Biol. Chem., August 26, 2005; 280(34): 30542 - 30549. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wang, H. M. Curry, B. S. Zwilling, and W. P. Lafuse Mycobacteria Inhibition of IFN-{gamma} Induced HLA-DR Gene Expression by Up-Regulating Histone Deacetylation at the Promoter Region in Human THP-1 Monocytic Cells J. Immunol., May 1, 2005; 174(9): 5687 - 5694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Zhou, J. B. Trudeau, K. J. Schoonover, J. I. Lundin, S. M. Barnes, M. J. Cundall, and S. E. Wenzel Interleukin-13 augments transforming growth factor-{beta}1-induced tissue inhibitor of metalloproteinase-1 expression in primary human airway fibroblasts Am J Physiol Cell Physiol, February 1, 2005; 288(2): C435 - C442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. F. Quiroga, G. J. Martinez, V. Pasquinelli, M. A. Costas, M. M. Bracco, A. Malbran, L. M. Olivares, P. A. Sieling, and V. E. Garcia Activation of Signaling Lymphocytic Activation Molecule Triggers a Signaling Cascade That Enhances Th1 Responses in Human Intracellular Infection J. Immunol., September 15, 2004; 173(6): 4120 - 4129. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
